Eidogen-Sertanty Expands Japanese Distribution Channel with Informative Seminar Series

San Diego, CA (August 23, 2005) – Eidogen-Sertanty, Inc., a San Diego-based computational drug discovery solutions provider, and CTC Laboratory Systems (CTCLS), a Japan-based provider of life science informatics technologies, have expanded their distribution arrangement to allow CTCLS to distribute the full suite of Eidogen-Sertanty products in Japan. To announce the launch, CTCLS has held a series of seminars in Osaka and Tokyo, Japan to introduce Eidogen-Sertanty's suite of knowledge-driven drug discovery informatics solutions.

“We are excited to build on our recent successes with U.S. and European-based pharmaceutical companies by offering the full suite of Eidogen-Sertanty products and services in Japan via our distribution agreement with CTCLS,” said Dr. Steven Muskal, CEO of Eidogen-Sertanty. “We are confident that CTCLS's life science informatics expertise and long-standing relationships with Japanese pharmaceutical customers will help speed the adoption of the Eidogen-Sertanty product line in Japan.”

Highlights of the CTCLS seminar series included a presentation from Dr. Keana Scott of Celera Genomics, who provided a customer testimonial demonstrating how Celera has effectively utilized Eidogen-Sertanty's Target Informatics Platform and EVE comparative visualization software to enhance structural informatics workflows in Celera's kinase drug discovery projects.

Dr. Derek Debe, Chief Scientific Officer of Eidogen-Sertanty, held a seminar on the Target Informatics Platform (TIP), a comparative structural informatics knowledgebase that enables researchers to effectively utilize the rapidly expanding body of available protein structure data for more efficient lead discovery, lead optimization, and virtual screening. Dr. Debe also presented several case studies of the company's recently launched DirectDesign discovery service, a computational approach for integrating knowledge of available chemicals, synthetic feasibility, and proven biological activities to generate synthetically tractable, target-directed libraries which have higher enrichment rates than classical virtual ligand screening or de novo lead design approaches.

The seminar series was well attended by scientists from major Japanese pharmaceutical companies. “We received positive feedback from many seminar attendees, who found significant value in Eidogen-Sertanty's comprehensive drug discovery solution and appreciated the customer case study,” said Michihiro Tateishi, General Manager of Life-science Sales Department of CTCLS. “Eidogen-Sertanty offers a full suite of discovery informatics products that will enable us to accelerate our business as the leading provider of total information technology solutions.”

CTC Laboratory Systems
CTC Laboratory Systems Corporation, a subsidiary of ITOCHU TECHNO-SCIENCE Corporation, is Japan's leading provider of total information technology solutions for pharmaceutical, chemical, and food processing industries, as well as life sciences research institutions. For more information visit www.ctc-g.co.jp/en/ .

Eidogen-Sertanty, Inc.
Eidogen-Sertanty, formed in March 2005 from the merger of Eidogen and Sertanty, is a privately held company providing pioneering knowledge-driven discovery solutions to biotechnology and pharmaceutical organizations. Eidogen-Sertanty's unique and powerful suite of software, databases, and drug discovery services enable customers and collaborators to apply a knowledge-driven discovery approach to a variety of workflows and processes, including target selection and prioritization, library building and compound prioritization, and lead design and optimization. To find out more about Eidogen-Sertanty and their products and services please visit www.eidogen-sertanty.com .

Contact Information:
Steven Muskal
760-729-0211
pr@eidogen-sertanty.com